➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Boehringer Ingelheim
Medtronic
Dow
Mallinckrodt

Last Updated: May 15, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LURASIDONE HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for lurasidone hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00044005 Safety and Tolerability Study of Drug to Treat Schizophrenia Completed Sunovion Phase 2 2002-09-01 The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.
NCT00088621 A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia Completed Sunovion Phase 2 2004-07-01 A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia
NCT00088634 A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia Completed Sunovion Phase 2 2004-05-01 A 6-week in-patient and out-patient study to test the effectiveness and safety of a new medication in the treatment of schizophrenia
NCT00549666 A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects Completed Sunovion Phase 1 2007-08-01 A Phase 1, drug, drug, interaction study between Lurasidone HCl and Ortho-tri cyclen
NCT00549718 Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia Completed Sunovion Phase 3 2007-10-01 Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.
NCT00615433 Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia Completed Sunovion Phase 3 2008-01-01 Lurasidone HCl is a compound developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for lurasidone hydrochloride

Condition Name

Condition Name for lurasidone hydrochloride
Intervention Trials
Schizophrenia 35
Bipolar Depression 13
Bipolar Disorder 7
Schizoaffective Disorder 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for lurasidone hydrochloride
Intervention Trials
Schizophrenia 38
Bipolar Disorder 20
Depression 18
Depressive Disorder 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for lurasidone hydrochloride

Trials by Country

Trials by Country for lurasidone hydrochloride
Location Trials
United States 437
India 61
Japan 22
Ukraine 18
Russian Federation 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for lurasidone hydrochloride
Location Trials
California 37
New York 31
Texas 29
Florida 26
Pennsylvania 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for lurasidone hydrochloride

Clinical Trial Phase

Clinical Trial Phase for lurasidone hydrochloride
Clinical Trial Phase Trials
Phase 4 9
Phase 3 37
Phase 2/Phase 3 3
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for lurasidone hydrochloride
Clinical Trial Phase Trials
Completed 44
Recruiting 12
Not yet recruiting 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for lurasidone hydrochloride

Sponsor Name

Sponsor Name for lurasidone hydrochloride
Sponsor Trials
Sunovion 41
Sumitomo Dainippon Pharma Co., Ltd. 5
NeuroRx, Inc. 4
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for lurasidone hydrochloride
Sponsor Trials
Industry 64
Other 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Medtronic
Express Scripts
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.